Celgene (CELG - Free Report) closed the most recent trading day at $93.44, moving -0.28% from the previous trading session. This move lagged the S&P 500's daily of 0%. At the same time, the Dow lost 0.3%, and the tech-heavy Nasdaq gained 0.25%.
Prior to today's trading, shares of the biotechnology company had gained 9.28% over the past month. This has outpaced the Medical sector's loss of 0.21% and the S&P 500's gain of 2.36% in that time.
Wall Street will be looking for positivity from CELG as it approaches its next earnings report date. In that report, analysts expect CELG to post earnings of $2.49 per share. This would mark year-over-year growth of 21.46%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.01 billion, up 13.46% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $10.73 per share and revenue of $17.14 billion, which would represent changes of +20.97% and +12.17%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for CELG. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CELG currently has a Zacks Rank of #2 (Buy).
Digging into valuation, CELG currently has a Forward P/E ratio of 8.73. This valuation marks a discount compared to its industry's average Forward P/E of 21.43.
Investors should also note that CELG has a PEG ratio of 0.4 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.04 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 79, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.